After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Veradigm Inc. (MDRX) shows that investor sentiment remained same, with the stock’s consolidated last price remained same to $13.07. The Veradigm Inc. has recorded 18,048 volume in the after hours trading session. Recently, Yahoo Finance discussed the stock, revealing that Veradigm Inc. Provides Audit Update and Updates Financial Guidance for 2023.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Stocks Info
Veradigm Inc. is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Health Information Services industry. At the end of the last regular session, the stock closed at $13.07 and fluctuated between $13.35 as its day high and $11.81 as its day low. The current market capitalization of Veradigm Inc. is $1.46B. A total of 1.69 million shares were traded on the day, compared to an average of 856.30K shares.
Insider Activity
Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, MDRX has seen 1 BUY and 1 SELL insider trades, representing the acquisition of 366,302 and the disposition of 162,271 shares. Over the last 12 months, there were 3 BUYs and 29 SELLs from insiders. Insiders purchased 742,908 shares during that period but sold 567,361.
In the most recent transaction, Poulton Richard J. sold 10,000 shares of MDRX for 17.33 per share on Feb 16. After the transaction, the CEO now owns 669,017 company shares. In a previous transaction on Feb 15, Poulton Richard J. sold 10,000 shares at 17.38 per share. MDRX shares that CEO owns now total 679,017.
Among the insiders who sold shares, Vakharia Tejal disposed of 8,642 shares on Dec 12 at a per-share price of $18.42. This resulted in the SVP General Counsel holding 222,604 shares of MDRX after the transaction. In another insider transaction, Stevens David B sold 43,134 shares at $18.47 per share on Dec 06. Company shares held by the Director now total 32,384.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for MDRX in the last 3 months, the mean price target is $17.50 with high estimates of $26.00 and low estimates of $13.00. In terms of 52-week highs and lows, MDRX has a high of $19.77 and a low of $11.30.
As of this writing, MDRX has an earnings estimate of $Veradigm Inc. per share for the current quarter. EPS was calculated based on a consensus of GoodRx Holdings, Inc. estimates, with a high estimate of $Moleculin Biotech, Inc. per share and a lower estimate of $Biodexa Pharmaceuticals plc.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. MDRX’s latest balance sheet shows that the firm has $188.30M in Cash & Short Term Investments as of fiscal 2021. There were $434.50M in debt and $547.10M in liabilities at the time. Its Book Value Per Share was $10.68, while its Total Shareholder’s Equity was $1.41B.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for MDRX is Buy with a score of 4.00.
